10x Genomics Q1 revenue $134.3M (+17% YoY); net loss $50.7M; raises FY2023 guidance to $590-$610M

10x Genomics, Inc.

2023-Q1 EPS reported -$0.44 revenue$134,285,000

Revenue $134.3M (+17% YoY); spatial portfolio drove growth, Xenium in first full launch quarter.
Net loss $50.7M vs $42.4M in prior year; operating loss $52.0M incl $42.1M stock-based comp.
Gross margin 73% (down from 78%) due to product mix and inventory write-downs.
Raised FY2023 revenue guidance to $590-610M (prev $580-600M); 14-18% growth.
Cash and marketable securities $418.3M as of March 31.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

10x Genomics, Inc. reported first quarter ended March 31, 2023 results: revenue $134.3 million, net income $50.7 million. Guidance raised.

Period: first quarter ended March 31, 2023
Revenue: $134.3 million
Net income: $50.7 million
Guidance: raised
Result: reported results

Exact text from the filing

PLEASANTON, Calif. May 3, 2023 – 10x Genomics, Inc. (Nasdaq: TXG) today reported financial results for the first quarter ended March 31, 2023. Recent Highlights • Revenue was $134.3 million for the first quarter, representing a 17% increase over the corresponding period of 2022. • Surpassed 5,000 customer publications using 10x Genomics products, demonstrating the

View on SEC.gov

Browse all earnings releases →

10x Genomics, Inc. filing history →

Source: SEC EDGAR

accession 0001770787-23-000026

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.